Search

Your search keyword '"Banerjee, Amitava"' showing total 20 results
Start Over Author "Banerjee, Amitava" Journal heart
20 results on '"Banerjee, Amitava"'

1. Prevalence, outcomes and costs of a contemporary, multinational population with heart failure

Author

Norhammar, Anna, primary, Bodegard, Johan, additional, Vanderheyden, Marc, additional, Tangri, Navdeep, additional, Karasik, Avraham, additional, Maggioni, Aldo Pietro, additional, Sveen, Kari Anne, additional, Taveira-Gomes, Tiago, additional, Botana, Manuel, additional, Hunziker, Lukas, additional, Thuresson, Marcus, additional, Banerjee, Amitava, additional, Sundström, Johan, additional, and Bollmann, Andreas, additional

Published
2023
Full Text
View/download PDF

3. Smartphone detection of atrial fibrillation using photoplethysmography: a systematic review and meta-analysis

Author

Gill, Simrat, primary, Bunting, Karina V, additional, Sartini, Claudio, additional, Cardoso, Victor Roth, additional, Ghoreishi, Narges, additional, Uh, Hae-Won, additional, Williams, John A, additional, Suzart-Woischnik, Kiliana, additional, Banerjee, Amitava, additional, Asselbergs, Folkert W, additional, Eijkemans, MJC, additional, Gkoutos, Georgios V, additional, and Kotecha, Dipak, additional

Published
2022
Full Text
View/download PDF

4. Evaluation of antithrombotic use and COVID-19 outcomes in a nationwide atrial fibrillation cohort

Author

Handy, Alex, primary, Banerjee, Amitava, additional, Wood, Angela M, additional, Dale, Caroline, additional, Sudlow, Cathie L M, additional, Tomlinson, Christopher, additional, Bean, Daniel, additional, Thygesen, Johan H, additional, Mizani, Mehrdad A, additional, Katsoulis, Michail, additional, Takhar, Rohan, additional, Hollings, Sam, additional, Denaxas, Spiros, additional, Walker, Venexia, additional, Dobson, Richard, additional, and Sofat, Reecha, additional

Published
2022
Full Text
View/download PDF

5. Impact of cardiometabolic multimorbidity and ethnicity on cardiovascular/renal complications in patients with COVID-19

Author

Norris, Tom, primary, Razieh, Cameron, additional, Zaccardi, Francesco, additional, Yates, Thomas, additional, Islam, Nazrul, additional, Gillies, Clare L, additional, Chudasama, Yogini V, additional, Rowlands, Alex V, additional, Davies, Melanie J, additional, McCann, Gerry P, additional, Banerjee, Amitava, additional, Lam, Carolyn S P, additional, Docherty, Annemarie B, additional, Openshaw, Peter JM, additional, Baillie, J Kenneth, additional, Semple, Malcolm Gracie, additional, Lawson, Claire Alexandra, additional, and Khunti, Kamlesh, additional

Published
2021
Full Text
View/download PDF

8. Impact of cardiometabolic multimorbidity and ethnicity on cardiovascular/renal complications in patients with COVID-19.

Author

Norris, Tom, Razieh, Cameron, Zaccardi, Francesco, Yates, Thomas, Islam, Nazrul, Gillies, Clare L., Chudasama, Yogini V., Rowlands, Alex V., Davies, Melanie J., McCann, Gerry P., Banerjee, Amitava, Lam, Carolyn S. P., Docherty, Annemarie B., Openshaw, Peter J. M., Baillie, J. Kenneth, Semple, Malcolm Gracie, Lawson, Claire Alexandra, and Khunti, Kamlesh

Published
2022
Full Text
View/download PDF

9. Monitoring indirect impact of COVID-19 pandemic on services for cardiovascular diseases in the UK

Author

Ball, Simon, primary, Banerjee, Amitava, additional, Berry, Colin, additional, Boyle, Jonathan R, additional, Bray, Benjamin, additional, Bradlow, William, additional, Chaudhry, Afzal, additional, Crawley, Rikki, additional, Danesh, John, additional, Denniston, Alastair, additional, Falter, Florian, additional, Figueroa, Jonine D, additional, Hall, Christopher, additional, Hemingway, Harry, additional, Jefferson, Emily, additional, Johnson, Tom, additional, King, Graham, additional, Lee, Kuan Ken, additional, McKean, Paul, additional, Mason, Suzanne, additional, Mills, Nicholas L, additional, Pearson, Ewen, additional, Pirmohamed, Munir, additional, Poon, Michael T C, additional, Priedon, Rouven, additional, Shah, Anoop, additional, Sofat, Reecha, additional, Sterne, Jonathan A C, additional, Strachan, Fiona E, additional, Sudlow, Cathie L M, additional, Szarka, Zsolt, additional, Whiteley, William, additional, and Wyatt, Michael, additional

Published
2020
Full Text
View/download PDF

14. Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study.

Author

Banerjee, Amitava, Benedetto, Valerio, Gichuru, Philip, Burnell, Jane, Antoniou, Sotiris, Schilling, Richard J., Strain, William David, Ryan, Ronan, Watkins, Caroline, Marshall, Tom, and Sutton, Chris J.

Subjects
ATRIAL fibrillation, PERSISTENCE, MEDICAL care
Abstract

Background: Despite simpler regimens than vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF), adherence (taking drugs as prescribed) and persistence (continuation of drugs) to direct oral anticoagulants are suboptimal, yet understudied in electronic health records (EHRs).Objective: We investigated (1) time trends at individual and system levels, and (2) the risk factors for and associations between adherence and persistence.Methods: In UK primary care EHR (The Health Information Network 2011-2016), we investigated adherence and persistence at 1 year for oral anticoagulants (OACs) in adults with incident AF. Baseline characteristics were analysed by OAC and adherence/persistence status. Risk factors for non-adherence and non-persistence were assessed using Cox and logistic regression. Patterns of adherence and persistence were analysed.Results: Among 36 652 individuals with incident AF, cardiovascular comorbidities (median CHA2DS2VASc[Congestive heart failure, Hypertension, Age≥75 years, Diabetes mellitus, Stroke, Vascular disease, Age 65-74 years, Sex category] 3) and polypharmacy (median number of drugs 6) were common. Adherence was 55.2% (95% CI 54.6 to 55.7), 51.2% (95% CI 50.6 to 51.8), 66.5% (95% CI 63.7 to 69.2), 63.1% (95% CI 61.8 to 64.4) and 64.7% (95% CI 63.2 to 66.1) for all OACs, VKA, dabigatran, rivaroxaban and apixaban. One-year persistence was 65.9% (95% CI 65.4 to 66.5), 63.4% (95% CI 62.8 to 64.0), 61.4% (95% CI 58.3 to 64.2), 72.3% (95% CI 70.9 to 73.7) and 78.7% (95% CI 77.1 to 80.1) for all OACs, VKA, dabigatran, rivaroxaban and apixaban. Risk of non-adherence and non-persistence increased over time at individual and system levels. Increasing comorbidity was associated with reduced risk of non-adherence and non-persistence across all OACs. Overall rates of 'primary non-adherence' (stopping after first prescription), 'non-adherent non-persistence' and 'persistent adherence' were 3.5%, 26.5% and 40.2%, differing across OACs.Conclusions: Adherence and persistence to OACs are low at 1 year with heterogeneity across drugs and over time at individual and system levels. Better understanding of contributory factors will inform interventions to improve adherence and persistence across OACs in individuals and populations. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

20. Changes in renal function after catheter ablation of atrial fibrillation are associated with CHADS2 and CHA2DS2-VASc scores and arrhythmia recurrences.

Author

Kornej, Jelena, Hindricks, Gerhard, Banerjee, Amitava, Arya, Arash, Sommer, Philipp, Rolf, Sascha, Husser, Daniela, Lip, Gregory Y. H., and Bollmann, Andreas

Subjects
KIDNEYS, CATHETER ablation, ATRIAL fibrillation, ARRHYTHMIA, REGRESSION analysis
Abstract

Background Renal impairment is associated with poor prognosis in the setting of atrial fibrillation (AF). While AF catheter ablation is an effective treatment modality for AF burden reduction and improvement of symptoms, changes in renal function after catheter ablation and their association with rhythm outcome have not been studied in a large contemporary AF ablation cohort. Objective To determine the association between CHADS2 and CHA2DS2-VASc scores and arrhythmia recurrences with changes in renal function following AF catheter ablation. Methods Estimated glomerular filtration rate (eGFR) was estimated using the Chronic Kidney Disease Epidemiology Collaboration equation at baseline and during follow-up in 783 patients undergoing de novo AF catheter ablation. Complete rhythm follow-up was achieved in 626 patients (80%) using serial 7-day Holter ECG. Results The study population (n=783, 61±10 years, 64% men, 57% paroxysmal AF) was followed up at median 20 (IQR 12-27) months. Baseline eGFR correlated with CHADS2 (ß=--0.258, p<0.001) and CHA2DS2-VASc scores (ß=-0.434, p<0.001). On multivariable analyses, eGFR changes were associated with AF recurrences (B= -0.136, p=0.014), CHADS2 (B=-0.062, p=0.035) and CHA2DS2-VASc scores (B=-0.057, p=0.003). Conclusions In patients after AF catheter ablation, eGFR changes during mid-term follow-up are associated with AF recurrences, CHADS2 and CHA2DS2-VASc scores. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results